Perturbed CD8+ T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Tauriainen, Johanna ^a   Scharf, Lydia ^a   Frederiksen, Juliet ^b   Naji, Ali ^c   Ljunggren, Hans Gustaf ^a   Sönnerborg, Anders ^a   Lund, Ole ^b   Reyes Terán, Gustavo ^d   Hecht, Frederick M ^e   Deeks, Steven G ^e   Betts, Michael R ^c   Buggert, Marcus ^a,c   Karlsson, Annika C ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD226 ANTIGEN; IMMUNOGLOBULIN RECEPTOR; POLIOVIRUS RECEPTOR; T LYMPHOCYTE ANTIGEN; TIGIT PROTEIN, HUMAN; VIRUS RECEPTOR;

ADULT; CD8+ T LYMPHOCYTE; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; METABOLISM; MIDDLE AGED; PATHOGENICITY; SIGNAL TRANSDUCTION; VIROLOGY;

ADULT; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENE EXPRESSION REGULATION; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC; RECEPTORS, VIRUS; SIGNAL TRANSDUCTION;

EID: 85009812414     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep40354     Document Type: Article

References (51)

1. Zajac, A. J. et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 188, 2205-2213 (1998).
2. Goepfert, P. A. et al. A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon. J Virol 74, 10249-10255 (2000).
3. Kostense, S. et al. High viral burden in the presence of major HIV-specific CD8(+) T cell expansions: evidence for impaired CTL effector function. Eur J Immunol 31, 677-686, doi: 10.1002/1521-4141(200103)31:3 <677::AID-IMMU677>3.0.CO;2-M (2001).
4. Shankar, P. et al. Impaired function of circulating HIV-specific CD8(+) T cells in chronic human immunodeficiency virus infection. Blood 96, 3094-3101 (2000).
5. Wherry, E. J. T cell exhaustion. Nat Immunol 12, 492-499 (2011).
6. Day, C. L. et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443, 350-354, doi: 10.1038/nature05115 (2006).
7. Petrovas, C. et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 203, 2281-2292, doi: 10.1084/jem.20061496 (2006).
8. Trautmann, L. et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 12, 1198-1202, doi: 10.1038/nm1482 (2006).
9. Buggert, M. et al. T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection. PLoS Pathog 10, e1004251, doi: 10.1371/journal.ppat.1004251 (2014).
10. Yamamoto, T. et al. Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection. Blood 117, 4805-4815, doi: 10.1182/blood-2010-11-317297 (2011).
11. Peretz, Y. et al. CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction. PLoS Pathog 8, e1002840, doi: 10.1371/journal.ppat.1002840 (2012).
12. Vigano, S. et al. CD160-associated CD8 T-cell functional impairment is independent of PD-1 expression. PLoS Pathog 10, e1004380, doi: 10.1371/journal.ppat.1004380 (2014).
13. Pombo, C., Wherry, E. J., Gostick, E., Price, D. A. & Betts, M. R. Elevated Expression of CD160 and 2B4 Defines a Cytolytic HIVSpecific CD8+ T-Cell Population in Elite Controllers. J Infect Dis 212, 1376-1386, doi: 10.1093/infdis/jiv226 (2015).
14. Jones, R. B. et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 205, 2763-2779, doi: 10.1084/jem.20081398 (2008).
15. Kao, C. et al. Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. Nat Immunol 12, 663-671, doi: 10.1038/ni.2046 (2011).
16. Paley, M. A. et al. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 338, 1220-1225, doi: 10.1126/science.1229620 (2012).
17. Joller, N. et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol 186, 1338-1342, doi: 10.4049/jimmunol.1003081 (2011).
18. Stanietsky, N. et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci USA 106, 17858-17863, doi: 10.1073/pnas.0903474106 (2009).
19. Yu, X. et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol 10, 48-57, doi: 10.1038/ni.1674 (2009).
20. Liu, S. et al. Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells. Cell Death Differ 20, 456-464, doi: 10.1038/cdd.2012.141 (2013).
21. Johnston, R. J. et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 26, 923-937, doi: 10.1016/j.ccell.2014.10.018 (2014).
22. Chauvin, J. M. et al. TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients. J Clin Invest 125, 2046-2058, doi: 10.1172/JCI80445 (2015).
23. Chew, G. M. et al. TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection. PLoS Pathog 12, e1005349, doi: 10.1371/journal.ppat.1005349 (2016).
24. Blackburn, S. D., Shin, H., Freeman, G. J. & Wherry, E. J. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci USA 105, 15016-15021, doi: 10.1073/pnas.0801497105 (2008).
25. Peligero, C. et al. PD-L1 Blockade Differentially Impacts Regulatory T Cells from HIV-Infected Individuals Depending on Plasma Viremia. PLoS Pathog 11, e1005270, doi: 10.1371/journal.ppat.1005270 (2015).
26. Fromentin, R. et al. CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART. PLoS Pathog 12, e1005761, doi: 10.1371/journal.ppat.1005761 (2016).
27. Cella, M. et al. Loss of DNAM-1 contributes to CD8+ T-cell exhaustion in chronic HIV-1 infection. Eur J Immunol 40, 949-954, doi: 10.1002/eji.200940234 (2010).
28. Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450-461, doi: 10.1016/j.ccell.2015.03.001 (2015).
29. Masson, D. et al. Overexpression of the CD155 gene in human colorectal carcinoma. Gut 49, 236-240 (2001).
30. Merrill, M. K. et al. Poliovirus receptor CD155-targeted oncolysis of glioma. Neuro Oncol 6, 208-217, doi: 10.1215/S1152851703000577 (2004).
31. Matusali, G., Potesta, M., Santoni, A., Cerboni, C. & Doria, M. The human immunodeficiency virus type 1 Nef and Vpu proteins downregulate the natural killer cell-activating ligand PVR. J Virol 86, 4496-4504, doi: 10.1128/JVI.05788-11 (2012).
32. Vassena, L., Giuliani, E., Matusali, G., Cohen, E. A. & Doria, M. The human immunodeficiency virus type 1 Vpr protein upregulates PVR via activation of the ATR-mediated DNA damage response pathway. J Gen Virol 94, 2664-2669, doi: 10.1099/vir.0.055541-0 (2013).
33. Lindqvist, M. et al. Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J Clin Invest 122, 3271-3280, doi: 10.1172/JCI64314 (2012).
34. Perreau, M. et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med 210, 143-156, doi: 10.1084/jem.20121932 (2013).
35. Hecht, F. M. et al. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS 16, 1119-1129 (2002).
36. Hunt, P. W. et al. A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS One 6, e15924, doi: 10.1371/journal.pone.0015924 (2011).
37. Buggert, M. et al. Multiparametric bioinformatics distinguish the CD4/CD8 ratio as a suitable laboratory predictor of combined T cell pathogenesis in HIV infection. J Immunol 192, 2099-2108, doi: 10.4049/jimmunol.1302596 (2014).
38. Buggert, M., Norstrom, M. M., Salemi, M., Hecht, F. M. & Karlsson, A. C. Functional avidity and IL-2/perforin production is linked to the emergence of mutations within HLA-B∗5701-restricted epitopes and HIV-1 disease progression. J Immunol 192, 4685-4696, doi: 10.4049/jimmunol.1302253 (2014).
39. Amir el, A. D. et al. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat Biotechnol 31, 545-552, doi: 10.1038/nbt.2594 (2013).
40. Roederer, M., Nozzi, J. L. & Nason, M. C. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 79, 167-174, doi: 10.1002/cyto.a.21015 (2011).
41. Sainz, T. et al. The CD4/CD8 ratio as a marker T-cell activation, senescence and activation/exhaustion in treated HIV-infected children and young adults. AIDS 27, 1513-1516, doi: 10.1097/QAD.0b013e32835faa72 (2013).
42. Appay, V. et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 8, 379-385, doi: 10.1038/nm0402-379 (2002).
43. Appay, V. et al. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 192, 63-75 (2000).
44. Betts, M. R. et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107, 4781-4789, doi: 10.1182/blood-2005-12-4818 (2006).
45. Almeida, J. R. et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 204, 2473-2485, doi: 10.1084/jem.20070784 (2007).
46. Lorenzo-Redondo, R. et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature 530, 51-56, doi: 10.1038/nature16933 (2016).
47. Lozano, E., Dominguez-Villar, M., Kuchroo, V. & Hafler, D. A. The TIGIT/CD226 axis regulates human T cell function. J Immunol 188, 3869-3875, doi: 10.4049/jimmunol.1103627 (2012).
48. Gilfillan, S. et al. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med 205, 2965-2973, doi: 10.1084/jem.20081752 (2008).
49. Deeks, S. G. HIV: Shock and kill. Nature 487, 439-440, doi: 10.1038/487439a (2012).
50. Connick, E. et al. CTL fail to accumulate at sites of HIV-1 replication in lymphoid tissue. J Immunol 178, 6975-6983 (2007).
51. Fukazawa, Y. et al. B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat Med 21, 132-139, doi: 10.1038/nm.3781 (2015).